SCHEMBL987461

SCHEMBL987461

CCCCOC(=O)CCC(=O)CN

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.86
DGKA P23743 1/20 0.52
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
NAAA Q02083 1/20 0.47
ALDH1A1 P00352 3/20 0.47
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45
PRSS3 P35030 1/20 0.45
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
CNR1 P21554 1/20 0.44
ATM Q13315 1/20 0.44
FAAH O00519 1/20 0.43
DNM1 Q05193 1/20 0.43
CYP1A2 P05177 1/20 0.42
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA1A P35348 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL987595 0.94 HTR2C (0.96) HTR2CDGKAKDM4ELMNANAAA
SCHEMBL3819717 0.93 HTR2C (1.00) HTR2CDGKAKDM4ELMNANAAA
Hexaminolevulinate SCHEMBL1070663 0.93 HTR2C (1.00) HTR2CDGKAKDM4ELMNANAAA
SCHEMBL3829077 0.93 HTR2C (1.00) HTR2CDGKAKDM4ELMNANAAA
SCHEMBL3822217 0.93 HTR2C (1.00) HTR2CDGKAKDM4ELMNANAAA
SCHEMBL3822297 0.93 HTR2C (1.00) HTR2CDGKAKDM4ELMNANAAA
SCHEMBL3824698 0.93 HTR2C (1.00) HTR2CDGKAKDM4ELMNANAAA
Hexaminolevulinate SCHEMBL937621 0.91 HTR2C (0.97) HTR2CDGKAKDM4ELMNANAAA
Hydrochloric Acid SCHEMBL1613756 0.91 HTR2C (0.97) HTR2CDGKAKDM4ELMNANAAA
Hydrochloric Acid SCHEMBL1613827 0.91 HTR2C (0.97) HTR2CDGKAKDM4ELMNANAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114287438-A Composition containing 5-aminolevulinic acid and metal salt of chlorophyllin 季红进 2022-04-08 CN claimed
CN-113875778-A Biostimulant comprising plant immunoactive protein and 5-aminolevulinic acid or derivative thereof 季红进 2022-01-04 CN claimed
EP-2272538-B1 METHOD OF DETECTING BLADDER CANCER SBI PHARMACEUTICALS CO LTD (JP) 2020-09-02 EP claimed
CN-105534739-A Plural gel HANGZHOU HUIKANG MEDICAL DEVICES CO LTD 2016-05-04 CN claimed
CN-104524576-A Use of aminolevulinic acid and derivatives thereof PHOTOCURE ASA 2015-04-22 CN claimed
CN-101896203-A Use of solid forms of 5-aminolevulinic acid and derivatives in photodynamic therapy and diagnosis PHOTOCURE ASA 2010-11-24 CN claimed
CN-101631541-A Application of aminolevulinic acid and derivatives thereof PHOTOCURE ASA 2010-01-20 CN claimed
EP-1467706-B1 DERMAL APPLICATION SYSTEM FOR AMINOLEVULINIC ACID-DERIVATIVES PHOTONAMIC GMBH & CO KG (DE) 2007-03-14 EP claimed
US-20060018956-A1 Dermal application system for aminolevulinic acid-derivatives PHOTONAMIC GMBH & CO. KG (DE) 2006-01-26 US claimed
EP-4548917-A1 NON-AQUEOUS PREPARATION WITH EXCELLENT STABILITY Kiyan Pharma Co., Ltd. (JP) 2025-05-07 EP disclosed
CN-119874643-A Paclitaxel prodrug, and preparation method and application thereof 中国药科大学 2025-04-25 CN disclosed
CN-119365191-A Nonaqueous formulations with excellent stability 基扬制药有限公司 2025-01-24 CN disclosed
US-20240299588-A1 NERVE LABEL UCL Business Ltd, University College London (GB) 2024-09-12 US disclosed
EP-4370166-A1 NERVE LABEL UCL Business Ltd (GB) 2024-05-22 EP disclosed
US-20080227757-A1 Formulation for dermal application TECHNISCHE UNIVERSITAT BRAUNSCHWEIG (DE) 2008-09-18 US disclosed
US-7135162-B2 Agent for diagnosing and treating malignant tumors COSMO RESEARCH INSTITUTE (JP) 2006-11-14 US disclosed
US-20060018956-A1 Dermal application system for aminolevulinic acid-derivatives PHOTONAMIC GMBH & CO. KG (DE) 2006-01-26 US disclosed
US-6905671-B1 Diagnostic agents and remedies for malignant tumors COSMO RESEARCH INSTITUTE (JP) 2005-06-14 US disclosed
US-20030065029-A1 Agent for diagnosing and treating malignant tumors COSMO RESEARCH INSTITUTE, COSMO OIL CO., LTD. 2003-04-03 US disclosed
EP-0995448-A1 DIAGNOSTIC AGENTS AND REMEDIES FOR MALIGNANT TUMORS Cosmo Research Institute (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299588-A1 NERVE LABEL GAP43, NT5M, NT5E HTR2C 2314/4885DGKA 4456/4885KDM4E 1008/4885
US-20030065029-A1 Agent for diagnosing and treating malignant tumors ALAD, VHL, AADAT HTR2C 2838/4885DGKA 4509/4885KDM4E 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.